Stem cell co Pluristem awarded $8.7m EU grant

Zami Aberman
Zami Aberman

The grant from the EU R&D Horizon 2020 program is for the Haifa based company's Phase III study of PLX-PAD cells to support recovery following surgery for femoral neck (hip) fracture.

Israeli placenta-based cell therapy product developer Pluristem Therapeutics Ltd. (TASE: PSTI; Nasdaq:PSTI) announced today that it has been awarded an $8.7 million (€7.4 million) grant from the EU. The grant from the EU R&D Horizon 2020 program is for the Haifa based company's Phase III study of PLX-PAD cells to support recovery following surgery for femoral neck (hip) fracture. Final approval of the grant is subject to the finalization of the consortium and Horizon 2020 grant agreements. This is the second such grant won by a Pluristem Phase III trial from Horizon 2020, following an $8 million (€7.6 million) award for its ongoing Phase III study of PLX-PAD cells in the treatment of Critical Limb Ischemia (CLI), which was given in August 2016.

The Phase III trial of PLX-PAD cells in the treatment of femoral neck fracture will be a collaborative effort between Pluristem and an international consortium led by the Charité - Universitätsmedizin Berlin, under the leadership of Dr. Tobias Winkler, Principal Investigator at the Berlin-Brandenburg Center for Regenerative Therapies, Julius Wolff Institute and Center for Musculoskeletal Surgery. Dr. Winkler also served as Senior Scientist for Pluristem’s completed Phase I/II study of PLX-PAD for hip surgery. That trial demonstrated that patients treated with Pluristem’s PLX-PAD cells during total hip arthroplasty experienced significant muscle regeneration compared to the control group with an improvement in muscle force and in muscle volume six months after surgery.

Dr. Winkler said, “Following the impressive results from the Phase I/II study of PLX-PAD cells in a similar orthopedic indication, we are excited to advance PLX-PAD cell therapy into a Phase III study to aid in muscle regeneration in patients recovering from femoral neck fracture. If similar results are achieved in this Phase III trial, it could show that PLX-PAD cells can improve outcomes in these procedures and change the way recovery is managed worldwide.”

Femoral neck fracture is the most common form of hip fracture, with mortality rates of up to 36%, and annual treatment costs are estimated to be between $10-$15 billion in the US alone. The number of surgeries performed annually to treat femoral neck fractures is increasing as populations age. Following surgery, many patients do not regain their baseline capabilities due to poor muscle healing and regeneration, which leads to significantly increased morbidity and a lower quality of life.

Pluristem chairman and CEO Zami Aberman said, “We are honored to receive this second grant from the Horizon 2020 program. We believe this grant reflects a vote of confidence by the EU and signals the need for cell therapy solutions to enable patients to lead healthier lives and to relieve health systems’ financial burdens. We are confident that this grant will help us move towards rapid entry into the European and US markets.” Pluristem’s PLX-PAD program is one of only a handful to be accepted into Europe’s Adaptive Pathway program, the purpose of which is to shorten the time it takes for innovative medicines to reach patients with serious conditions that lack adequate treatment options. Pluristem plans to enroll patients at clinical sites throughout Europe and the US. The study is expected to serve as a pivotal trial for regulatory approval in both regions.

Published by Globes [online], Israel business news - www.globes-online.com - on September 6, 2017

© Copyright of Globes Publisher Itonut (1983) Ltd. 2017

Zami Aberman
Zami Aberman
Shekel credit: Shutterstock Vladirina 32 Shekel gains continue as Gaza talks progress

The shekel continues to trade at its strongest levels against the dollar since early 2023.

New York credit: Shutterstock Tel Aviv - New York fares stay high despite US airlines return

Ticket prices to the US will continue to cost at least $1,200 return, according to Ophir Tours, with most fares ranging between $1,500 and $2,000, or even more.

Greenfield Partners team credit: Eyal Toueg Greenfield Partners closes $400m third fund

The funds were raised from institutional investors in Israel, the US, Europe and Asia and brings the total funds under management to more than $1 billion.

Blockaid founders Ido Ben-Natan and Raz Niv credit: Liron Weissman Israeli onchain security co Blockaid raises $50m

Blockaid protects the largest companies building onchain, including Coinbase, Metamask, Stellar, Uniswap, and World App.

Air Haifa  credit: ATR Air Haifa to launch Paphos flights

New Israeli airline Air Haifa will launch a new route between Haifa and Paphos in Cyprus on April 3, 2025 with six weekly flights.

Bladeranger Deepsolar credit: PR Bladeranger divests Deepsolar to Painreform in strategic move

Deepsolar, acquired by Bladeranger in early 2023, is a sophisticated software solution designed to optimize the management of photovoltaic solar energy fields.

Traffic jam on the Ayalon Highway in Tel Aviv credit: Shutterstock Tender issued for operating Tel Aviv congestion charge

Minister of Transport Miri Regev has dropped her opposition to the project, reportedly in exchange for financing railways to Kiryat Shmona and Eilat.

Ilya Sutskever credit: Cadya Levy Ilya Sutskever's SSI raising money at $30b valuation - report

The AI startup founded last year by OpenAI founder and former chief scientist Ilya Sutskever, is in talks to raise money at a company valuation of over $30 billion, "Bloomberg" reports.

Dina Ben Tal Ganancia  credit: Guy Kushi & Yariv Fein El Al stock still rising despite return of foreign airlines

The Israeli carrier's share price has risen 35% since the start of the year and some analysts predict further gains.

NIS 200 bills credit: Tali Bogdanovsky Reduction in cash holdings after NIS 200 bill abolishment talk

Since September 2024 there has been a dramatic decline in the number of NIS 200 bills held by the public relative to the number of NIS 100 bills, according to Bank of Israel data.

Teva CEO Richard Francis credit: Elad Malka Teva CEO responds to 25% share price fall

Richard Francis said that the question is no longer whether Teva will survive but whether it can grow more.

Holon employment bureau credit: Eyal Izhar Unemployment in Israel fell in January

The unemployment rate in Israel fell to 2.6% in January 2025, after seasonal adjustment, from 2.7% in December 2024, the Central Bureau of Statistics reports.

Dizengoff Center credit: Guy Hamoy Israel's economy grew 1% in 2024, above expectations

This figure reflects negative GDP per capita growth of 0.3%, because of population growth last year, the Central Bureau of Statistics reports.

Shalev Hulio and Sebastian Kutz credit: Pini Siluk and Dominic Butzmann Israeli co Dream Security raises $100m at $1.1b valuation

The company, which protects national infrastructures, was founded by former spyware company NSO Group CEO Shalev Hulio, former Austrian Chancellor Sebastian Kurz and Gil Dolev.

CyberArk CEO Matt Cohen and founder and executive chairman  Ehud Mokady  credit: PR $20b CyberArk becomes Israel's second most valuable co

The cybersecurity company's share price has almost tripled in value in the past three years.

Israel Tax Authority Head Shay Aharonovich credit: Yossi Zamir Israel Tax Authority set to publish voluntary disclosure plan

The latest procedure, delayed for over a year, will not include an anonymous track but will have a fast track for unreported cryptocurrency assets.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018